Duffy M J, Shering S, Sherry F, McDermott E, O'Higgins N
Department of Nuclear Medicine, St Vincent's University Hospital, Dublin, Ireland.
Int J Biol Markers. 2000 Oct-Dec;15(4):330-3. doi: 10.1177/172460080001500410.
CA 15-3 (also known as MUC1) is the most widely used serum marker in breast cancer. MUC1 is a large transmembrane glycoprotein which is frequently overexpressed and aberrantly glycosylated in cancer. Physiologically, MUC1 appears to play a role in cell adhesion and the high levels present in cancer may be causally involved in metastasis. At present the main uses of CA 15-3 are in preclinically detecting recurrent breast cancer and monitoring the treatment of patients with advanced breast cancer. In a prospective study of 368 patients we show that patients with high preoperative levels of CA 15-3 (>30.4 U/mL) had a worse outcome than patients with low levels of the marker. In multivariate analysis CA 15-3 as a prognostic marker was independent of both tumor size and nodal status. Furthermore, in multivariate analysis the prognostic impact of CA 15-3 was stronger than that of tumor size and at least as strong as nodal status. CA 15-3 may thus be the first independent prognostic serum marker in breast cancer.
CA 15-3(也称为MUC1)是乳腺癌中使用最广泛的血清标志物。MUC1是一种大型跨膜糖蛋白,在癌症中经常过度表达且糖基化异常。在生理情况下,MUC1似乎在细胞黏附中起作用,癌症中其高水平可能与转移有因果关系。目前CA 15-3的主要用途是临床前检测复发性乳腺癌以及监测晚期乳腺癌患者的治疗情况。在一项对368例患者的前瞻性研究中,我们发现术前CA 15-3水平高(>30.4 U/mL)的患者比该标志物水平低的患者预后更差。在多变量分析中,CA 15-3作为一种预后标志物独立于肿瘤大小和淋巴结状态。此外,在多变量分析中,CA 15-3的预后影响比肿瘤大小更强,且至少与淋巴结状态一样强。因此,CA 15-3可能是乳腺癌中首个独立的预后血清标志物。